What to do now

My marketocracy funds continue to beat the market…My long-only fund is up nearly 32% since inception (August 2001, a rather inauspicious start time), compared to the S&P500’s nearly 18% loss. My short-only fund is up 43% since inception (January 2005) compared to the S&P’s 21% loss, with limited shorting (overall, a 8.25% annualized return [...]

Briefcase cleaning

Funny story. I was cleaning out my briefcase and came across three old stock reports that I wrote for an interview last year with a fund manager. I didn’t get the job due to my “inexperience, particularly with foreign stocks (which admittedly I didn’t have a lot of experience with). Anyway, the stocks were: Celanese [...]

Another day, another 10% swing

Gee, this volatility (http://finance.yahoo.com/echarts?s=%5EGSPC#symbol=%5EGSPC;range=1d) is getting to be almost boring. I don’t pretend to be a technician but it does appear that the market is trying to bottom out around 800-850 on the S&P.
I was fortunate enough to catch some high quality names closer to the low than the high today, and [...]

Broadening Perspectives

I’ve decided to make this blog about a bit more than biotechnology investing.  I’ve added two links to my “mutual funds” at Marketocracy.com on the left.  I started these funds on a whim, the long-only fund way back in 2001 and the short-only fund when that option became available on the site back in 2005, [...]

Amylin hit again

Amylin took a 26% hit today on the FDA rejecting its equivalence study of exenatide LAR made at Alkermes and at Amylin’s facilities.  This probably takes away first-mover advantage on a long-acting exenatide from AMLN (when compared with liraglutide from Novo) and increases the likelihood of another commercial failure with exenatide LAR (along with Byetta)